CoChat

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body weight in obese subjects through increased energy expenditure and decreased energy intake. The metabolic effects of OXM have been attributed primarily to GLP1R agonism. We examined whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist. RESEARCH DESIGN AND METHODS: We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics. The metabolic effects of these two peptides with respect to weight loss, caloric reduction, glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice. Acute studies in DIO mice revealed metabolic pathways that were modulated independent of weight loss. Studies in Glp1r−/− and Gcgr−/− mice enabled delineation of the contribution of GLP1R versus GCGR activation to the pharmacology of DualAG. RESULTS: Peptide DualAG exhibits superior weight loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG. Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG. Dual receptor agonism also increased fatty acid oxidation and reduced hepatic steatosis in DIO mice. The antiobesity effects of DualAG require activation of both GLP1R and GCGR. CONCLUSIONS: Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-0278

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Sequence alignment and receptor agonist potencies of OXM and related peptides. A: Sequence alignment of OXM, exendin-4, and related glucagon superfamily peptides including the long acting OXM analogs DualAG and GLPAG. Conserved residues are highlighted. Gln3 is important for GCGR agonist activity. DualAG and GLPAG incorporate a DSer2 (S) substitution that confers resistance to DPP-4. The cholesterol moiety (chol) at the C-terminus of these peptides enhances metabolic stability and receptor affinity, and the intervening polyethylene glycol spacer minimizes the loss in agonist potency because of plasma protein/lipid binding. B: In vitro receptor agonist potencies (cAMP release) against mGLP1R and mGCGR and ED50 (nM) in the ex vivo mouse liver glycogenolysis assay (mGlyco). The Gln3→ Glu substitution in GLPAG reduces GCGR agonist activity ∼120- to 400-fold compared with DualAG.
FIG. 1. Sequence alignment and receptor agonist potencies of OXM and related peptides. A: Sequence alignment of OXM, exendin-4, and related glucagon superfamily peptides including the long acting OXM analogs DualAG and GLPAG. Conserved residues are highlighted. Gln3 is important for GCGR agonist activity. DualAG and GLPAG incorporate a DSer2 (S) substitution that confers resistance to DPP-4. The cholesterol moiety (chol) at the C-terminus of these peptides enhances metabolic stability and receptor affinity, and the intervening polyethylene glycol spacer minimizes the loss in agonist potency because of plasma protein/lipid binding. B: In vitro receptor agonist potencies (cAMP release) against mGLP1R and mGCGR and ED50 (nM) in the ex vivo mouse liver glycogenolysis assay (mGlyco). The Gln3→ Glu substitution in GLPAG reduces GCGR agonist activity ∼120- to 400-fold compared with DualAG.CC BY-NC-ND · PubMed Central
FIG. 2. Superior efficacy of a long-acting dual GLP1/GCGR agonist in reducing body weight in DIO mice. A: Study protocol for chronic dosing of animals with vehicle or peptides DualAG and GLPAG (1.9 μmol/kg subcutaneously, every other day). B: Cumulative changes in body weight. Plasma exposures of each peptide measured at the end of the study were comparable (inset). C: Cumulative food intake and (D) body composition changes for each treatment group. E: IPGTT conducted on day 13 of the study. *P < 0.05, DualAG and GLPAG versus vehicle; ∧P < 0.05, DualAG versus GLPAG.
FIG. 2. Superior efficacy of a long-acting dual GLP1/GCGR agonist in reducing body weight in DIO mice. A: Study protocol for chronic dosing of animals with vehicle or peptides DualAG and GLPAG (1.9 μmol/kg subcutaneously, every other day). B: Cumulative changes in body weight. Plasma exposures of each peptide measured at the end of the study were comparable (inset). C: Cumulative food intake and (D) body composition changes for each treatment group. E: IPGTT conducted on day 13 of the study. *P < 0.05, DualAG and GLPAG versus vehicle; ∧P < 0.05, DualAG versus GLPAG.CC BY-NC-ND · PubMed Central
FIG. 3. Histological analysis (photomicrographs) of lipid accumulation in liver obtained from DIO mice treated chronically with DualAG and GLPAG. Hematoxylin-eosin stain of hepatic histological sections obtained from animals treated with vehicle (A), DualAG (B), and GLPAG (C). Magnification ×300.
FIG. 3. Histological analysis (photomicrographs) of lipid accumulation in liver obtained from DIO mice treated chronically with DualAG and GLPAG. Hematoxylin-eosin stain of hepatic histological sections obtained from animals treated with vehicle (A), DualAG (B), and GLPAG (C). Magnification ×300.CC BY-NC-ND · PubMed Central
FIG. 4. Gene expression and metabolite changes measured in liver tissue obtained from DIO mice treated with vehicle, DualAG, or GLPAG. A–C: Pck1 (A), Pgc-1α (B), and Pdha1 (C) mRNA. D and E: Acetyl-CoA (D) and malonyl-CoA (E) levels. F–I: Fgf21 (F), Cpt1a (G), ChREBP (H), and Ldlr mRNA (I). *P < 0.05 DualAG and GLPAG versus vehicle; ∧P < 0.05 DualAG versus GLPAG.
FIG. 4. Gene expression and metabolite changes measured in liver tissue obtained from DIO mice treated with vehicle, DualAG, or GLPAG. A–C: Pck1 (A), Pgc-1α (B), and Pdha1 (C) mRNA. D and E: Acetyl-CoA (D) and malonyl-CoA (E) levels. F–I: Fgf21 (F), Cpt1a (G), ChREBP (H), and Ldlr mRNA (I). *P < 0.05 DualAG and GLPAG versus vehicle; ∧P < 0.05 DualAG versus GLPAG.CC BY-NC-ND · PubMed Central
FIG. 5. DualAG lowers body weight and food intake via activation of GLP1R and GCGR. Effect of repeated injections of DualAG or GLPAG on cumulative food intake and body weight in wild-type (A and B), Glp1r−/− (C and D), and Gcgr−/− (E and F) mice. The antiobesity effects of DualAG are attenuated but not ablated in either receptor knockout mouse. G: Proposed mechanism of action of DualAG. In addition to the known effects associated with GLP1R activation, hepatic GCGR activation increases liver glucose production and stimulates FAO. The acetyl-CoA generated by β-oxidation challenges the processing capacity of the tricarboxylic acid (TCA) cycle and is used in the biosynthesis of ketone bodies. Consistent with the decrease in plasma cholesterol, animals treated with DualAG showed a robust upregulation of liver LDLr expression. In the adipose tissue, pharmacological activation of GCGR and GLP1R may stimulate hydrolysis of triglycerides (TG). Upregulation of liver Fgf21 in animals treated with DualAG may contribute to stimulation of FAO and ketogenesis. *P < 0.05 DualAG and GLPAG versus vehicle; ∧P < 0.05 DualAG versus GLPAG. FFA, free fatty acid.
FIG. 5. DualAG lowers body weight and food intake via activation of GLP1R and GCGR. Effect of repeated injections of DualAG or GLPAG on cumulative food intake and body weight in wild-type (A and B), Glp1r−/− (C and D), and Gcgr−/− (E and F) mice. The antiobesity effects of DualAG are attenuated but not ablated in either receptor knockout mouse. G: Proposed mechanism of action of DualAG. In addition to the known effects associated with GLP1R activation, hepatic GCGR activation increases liver glucose production and stimulates FAO. The acetyl-CoA generated by β-oxidation challenges the processing capacity of the tricarboxylic acid (TCA) cycle and is used in the biosynthesis of ketone bodies. Consistent with the decrease in plasma cholesterol, animals treated with DualAG showed a robust upregulation of liver LDLr expression. In the adipose tissue, pharmacological activation of GCGR and GLP1R may stimulate hydrolysis of triglycerides (TG). Upregulation of liver Fgf21 in animals treated with DualAG may contribute to stimulation of FAO and ketogenesis. *P < 0.05 DualAG and GLPAG versus vehicle; ∧P < 0.05 DualAG versus GLPAG. FFA, free fatty acid.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 409

Metadata

Authors
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., Bianchi, E., Pessi, A., Marsh, D. J., & SinhaRoy, R.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Istituto di Ricerche di Biologia Molecolare P. Angeletti, Pomezia, Rome, Italy.
Corresponding author
  • Marsh, Donald J.
  • SinhaRoy, Ranabir
Venue
Diabetes
Published
2009-07-14
Volume
58
Issue
10
Pages
2258-2266
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2122188063
Cited by
409
References
47
Citations by year
2026: 10 · 2025: 15 · 2024: 32 · 2023: 25 · 2022: 18 · 2021: 25 · 2020: 30 · 2019: 28 · 2018: 38 · 2017: 25 · 2016: 29 · 2015: 28 · 2014: 20 · 2013: 29 · 2012: 24
FWCI
8.31
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
glucagon-like peptide-1, glucagon receptor, oxyntomodulin, obesity, diet-induced obesity, weight loss, lipid lowering, hypoglycemic effect, fatty acid oxidation, hepatic steatosis, insulin, leptin, adiponectin
MeSH terms
Glucagon-Like Peptide-1 Receptor, Amino Acid Sequence, Animals, Body Weight, Energy Intake, Cricetulus, Diabetes Mellitus, Type 2, Dietary Fats, Cricetinae, Injections, Subcutaneous, Insulin, Mice, Inbred C57BL, Molecular Sequence Data, Obesity, Weight Loss, CHO Cells, Receptors, Glucagon, Reverse Transcriptase Polymerase Chain Reaction, Mice, Glucagon-Like Peptide 1, Oxyntomodulin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.